Vaccinia immune globulin - Emergent BioSolutions
Alternative Names: C-VIG; CNJ 016; NP 016 - Cangene; VIG; VIGIV - Emergent BioSolutionsLatest Information Update: 31 Mar 2022
At a glance
- Originator Cangene Corporation
- Developer Emergent BioSolutions
- Class Immunoglobulins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Smallpox
Most Recent Events
- 02 Feb 2022 Sanofi Pasteur Holding has been rebranded under Sanofi
- 13 Aug 2015 US Centers for Disease Control and Prevention exercises options for the supply of vaccinia immune globulin IV into the US Strategic National Stockpile
- 21 Feb 2014 Cangene Corporation has been acquired and merged into Emergent BioSolutions